Baxter/$BAX

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Baxter

Baxter offers a variety of medical supplies and equipment to providers. From its legacy operations, Baxter sells injectable therapies for use in care settings, including IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents. Baxter expanded its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment like hospital beds, operating room equipment, and patient monitoring tools to the portfolio. Baxter also sold its kidney care tools in early 2025.

Ticker

$BAX
Sector

Primary listing

NYSE

Employees

38,000

Baxter Metrics

BasicAdvanced
$12B
-
-$0.31
0.60
$0.80
2.85%

What the Analysts think about Baxter

Analyst ratings (Buy, Hold, Sell) for Baxter stock.

Bulls say / Bears say

Baxter lowered its 2025 earnings outlook to $2.42–$2.52 per share, falling short of analysts' estimate of $2.52. Shares dropped 23% to their lowest level since 2006, weighed down by weak IV fluid demand and production disruptions caused by Hurricane Helene (Reuters).
The company halted shipments of its Novum IQ Large Volume Pump after safety issues were reported, including two patient deaths. These incidents bring increased regulatory scrutiny and raise the risk of potential liabilities (Reuters).
Baxter’s Pharmaceuticals segment reported weakness, with injectable therapies declining by 1% and anesthesia sales down in the low double digits, pointing to persistent demand challenges in its core drug business (Reuters).
Data summarised monthly by Lightyear AI. Last updated on 6 Sept 2025.

Baxter Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Baxter Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $BAX

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

Oct1
Baxter
DividendPayment
$0.17Per share
FAQs